CLOs on the Move

Actavis

www.actavis.com

 
Actavis is a unique global specialty pharmaceutical company focused on developing, manufacturing and commercializing high quality affordable generic and innovative branded pharmaceutical products for patients around the world. The Company has global headquarters in Dublin, Ireland. Actavis markets a broad portfolio of branded pharmaceuticals and is focused on developing new medicines for patients suffering from diseases principally in the central nervous system, gastroenterology, women’s health, urology, cardiovascular, respiratory and anti-infective therapeutic categories. Actavis is also the world`s third-largest generics prescription drug manufacturer, marketing generic, branded generic, and Over-the-Counter (OTC) products in more than 60 countries. Actavis Global Operations has more than 35 ...
  • Number of Employees: 5K-10K
  • Annual Revenue: > $1 Billion
  • www.actavis.com
  • 400 Interpace Pkwy
    Parsippany, NY USA 07054
  • Phone: 862.261.7000

Executives

Name Title Contact Details
Robert Bailey
General Counsel Profile

Similar Companies

Quality of Life Health Services

Quality of Life Health Services is a Gadsden, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sterling Pharma Solutions

Sterling is a CDMO or contract development and manufacturing organisation (/contract manufacturer organisation) with facilities in the UK and US.

VistaGen

VistaGen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. The Company is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. VistaGen`s clinical-stage candidates are targeting multiple forms of anxiety and depression. They belong to a new class of drugs known as pherines, which are odorless, tasteless, neuroactive steroids that bind to distinct receptors on chemosensory neurons in the nasal passages and can impact the limbic amygdala without systemic uptake or direct activity on CNS neurons in the brain. VistaGen`s lead candidate, PH94B, is a nasally administered spray currently in multiple Phase 3 trials in the U.S., with results anticipated in 2022. Should ongoing Phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder. With an experienced leadership team, VistaGen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression.

Erfa Canada Inc

Erfa Canada Inc is a Westmount, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Clearworth Systems

Clearworth Systems is a Rumson, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.